When does the label say to call your doctor?
From the Patient Information that comes with Gonal-f RFF Redi-ject:
- Shortness of breath, swelling of the face, or itchy red bumps or hives (a severe allergic reaction): stop using the pen and go to the hospital right away.
- Symptoms of OHSS, including trouble breathing, severe lower stomach (pelvic) pain, decreased urine, nausea, vomiting, weight gain or diarrhea: stop using the pen and call your healthcare provider right away.
- Symptoms of an ectopic pregnancy, including stomach or pelvic pain especially on one side, shoulder, neck or rectal pain, nausea and vomiting: call your healthcare provider right away.
- Any side effect that bothers you or does not go away: tell your healthcare provider.
What are the most common Gonal-f RFF Redi-ject side effects?
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Gonal-f RFF Redi-ject.
Show the label table (9 rows)Hide table
| System organ class / adverse reaction | GONAL-f RFF, N=83 |
|---|---|
| Central and Peripheral Nervous System: Headache | 22 (26.5%) |
| Gastrointestinal System: Abdominal Pain | 10 (12.0%) |
| Gastrointestinal System: Nausea | 3 (3.6%) |
| Gastrointestinal System: Flatulence | 3 (3.6%) |
| Gastrointestinal System: Diarrhea | 3 (3.6%) |
| Neoplasm: Ovarian Cyst | 3 (3.6%) |
| Reproductive, Female: Ovarian Hyperstimulation | 6 (7.2%) |
| Application Site: Injection Site Pain | 4 (4.8%) |
| Application Site: Injection Site Inflammation | 2 (2.4%) |
Up to 3 cycles of ovulation induction in 83 oligo-anovulatory women (176 treatment cycles), compared with another recombinant FSH rather than placebo. Values are number of women with the reaction (%).
Show the label table (10 rows)Hide table
| System organ class / adverse reaction | GONAL-f RFF, N=237 |
|---|---|
| Gastrointestinal System: Abdominal Pain | 55 (23.2%) |
| Gastrointestinal System: Nausea | 19 (8.0%) |
| Body as a Whole- General: Abdomen Enlarged | 33 (13.9%) |
| Central and Peripheral Nervous System: Headache | 44 (18.6%) |
| Application Site Disorders: Injection Site Bruising | 23 (9.7%) |
| Application Site Disorders: Injection Site Pain | 13 (5.5%) |
| Application Site Disorders: Injection Site Inflammation | 10 (4.2%) |
| Application Site Disorders: Injection Site Reaction | 10 (4.2%) |
| Application Site Disorders: Application Site Edema | 6 (2.5%) |
| Reproductive, Female: Ovarian Hyperstimulation | 11 (4.6%) |
One ART (IVF or ICSI) cycle in 237 ovulatory women after GnRH agonist down-regulation, compared with another recombinant FSH rather than placebo. Values are number of women with the reaction (%).
Other numbers in the Adverse Reactions section
- Section 5.3OHSS occurred in 7.2% of 83 women in ovulation induction and 4.6% of 237 women in ART in the Gonal-f RFF trials.
- Section 5.6Multiple births made up 20% of live births with ovulation induction and 35.1% of live births with ART in the Gonal-f RFF trials.
- Section 6.2Reported after approval: allergic reactions including anaphylactoid reactions, asthma and blood clots (thromboembolism).
What serious risks does the Gonal-f RFF Redi-ject label warn about?
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
- Section 4Who should not use it. Women with a prior allergy to recombinant FSH, high FSH showing primary gonadal failure, uncontrolled thyroid, adrenal or pituitary disorders, sex-hormone-dependent tumors of the reproductive organs, pituitary or hypothalamic tumors, unexplained abnormal uterine bleeding, or ovarian cysts or enlargement not due to PCOS.
- Section 5.1Serious allergic reactions. Anaphylaxis and other serious allergic reactions, with trouble breathing, facial swelling, itching and hives, have been reported with Gonal-f and Gonal-f RFF. If one occurs, use is stopped.
- Section 5.2Abnormal ovarian enlargement. If the ovaries are abnormally enlarged on the last day of treatment, hCG is not given, to lower the chance of OHSS. Intercourse is prohibited with significant enlargement after ovulation because a ruptured cyst can cause internal bleeding.
- Section 5.3Ovarian hyperstimulation syndrome (OHSS). OHSS can progress rapidly to a serious condition with fluid build-up in the abdomen, chest and around the heart, and blood clots. It develops after treatment stops, peaking about 7 to 10 days later, and is more common, severe and longer if pregnancy occurs. Women are watched for at least two weeks after hCG.
Show 4 more risksShow fewer
- Section 5.4Lung and blood vessel complications. Serious lung problems and blood clots, with or without OHSS, have been reported with gonadotropins including Gonal-f RFF, including stroke, loss of a limb and, rarely, heart attack; in rare cases they caused death.
- Section 5.5Ovarian torsion. Twisting of the ovary has been reported, possibly linked to OHSS, pregnancy, past abdominal surgery, past torsion, ovarian cysts and polycystic ovaries.
- Section 5.6Multiple pregnancy and birth. Multiple pregnancies and births have been reported with all gonadotropins, including Gonal-f RFF.
- Section 5.8Ectopic pregnancy, miscarriage and ovarian tumors. Ectopic pregnancy may be more common in women undergoing ART (5.8). Miscarriage risk is increased with gonadotropins, though causality has not been established (5.9). Infrequent reports of ovarian tumors have not been shown to be caused by the drugs (5.10).
Does Gonal-f RFF Redi-ject have a boxed warning?
No. The current Gonal-f RFF Redi-ject label has no boxed warning.
How do I keep track of side effects in Dose Track?
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own.
Read moreRead less
The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
Frequently asked questions
What are the most common side effects of Gonal-f RFF Redi-ject?
For ovulation induction, headache (26.5%), abdominal pain (12.0%) and ovarian hyperstimulation (7.2%). For ART, abdominal pain (23.2%), headache (18.6%), abdominal enlargement (13.9%), injection site bruising (9.7%) and nausea (8.0%) (section 6.1, Tables 1 and 2).
How common is OHSS with Gonal-f RFF?
In the label's trials, OHSS occurred in 7.2% of 83 women having ovulation induction and 4.6% of 237 women having ART (section 5.3).
Can Gonal-f cause an allergic reaction?
Yes. Serious allergic reactions including anaphylaxis have been reported after approval with Gonal-f and Gonal-f RFF, with trouble breathing, facial swelling, itching and hives. The Patient Information says to stop using it and go to the hospital right away (section 5.1).
How often does Gonal-f RFF lead to twins or more?
In the label's trials, multiple births were 20% of live births with ovulation induction and 35.1% with ART (section 5.6).
Does Gonal-f RFF Redi-ject have a boxed warning?
No. The current label has no boxed warning. Its warnings cover allergic reactions, ovarian enlargement, OHSS, lung and blood clot complications, ovarian torsion and multiple births (section 5).
Related pages
Show similar medicinesShow fewer
Side effects for similar medicines
- Cetrotidecetrorelix acetate
- Clomidclomiphene citrate
- Crinoneprogesterone vaginal gel 4% and 8%
- Endometrinprogesterone vaginal insert
- Follistim AQ Cartridgefollitropin beta
- Ganirelixganirelix acetate
- Menopurmenotropins for injection
- Novarelchorionic gonadotropin
See also
Sources
- GONAL-f RFF Redi-ject (follitropin alfa) injection, for subcutaneous use, prescribing information, Patient Information and Instructions for Use. EMD Serono. DailyMed, version published April 7, 2025. DailyMed setid b6d11c45-b502-478e-bb28-2ff596ea259c
What Gonal-f RFF Redi-ject is approved forHide
Gonal-f RFF Redi-ject is a prefilled FSH pen approved to induce ovulation and pregnancy in oligo-anovulatory women whose infertility is functional and not due to primary ovarian failure, and to develop multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle (section 1). This page covers the Redi-ject pen label; the Gonal-f multi-dose vial has a separate label.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.
All side-effect pages · Dosing schedules · Missed dose guides · Compound guides